Pioglitazone for prevention of cognitive impairment: results and lessons
- PMID: 34146499
- DOI: 10.1016/S1474-4422(21)00140-X
Pioglitazone for prevention of cognitive impairment: results and lessons
Conflict of interest statement
I report personal fees from Wave pharmaceuticals and Ionis Pharmaceuticals for attending Advisory board meetings, personal fees from Roche diagnostics, Janssen, and Neuraxpharm for educational activities, and research grants to my institution from Biogen and Sage Therapeutics outside the submitted work.
Comment on
-
Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.Lancet Neurol. 2021 Jul;20(7):537-547. doi: 10.1016/S1474-4422(21)00043-0. Lancet Neurol. 2021. PMID: 34146512 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources